| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 117, 2330-2338, Copyright © 1985 by Endocrine Society
ARTICLES |
LJ Dorflinger and A Schonbrunn
Although purine nucleosides have been shown to regulate the secretion of several peptide and steroid hormones, effects on pituitary hormone release have not been reported. We show here that in the clonal GH4C1 pituitary cell line maximal concentrations of adenosine (greater than or equal to 50 microM) inhibited PRL and GH secretion by 40%. Adenosine deaminase abolished the inhibitory effect of adenosine but not that of SRIF or (-)N6(R-2-phenylisopropyl)adenosine (PIA), a nonhydrolyzable adenosine analog. Furthermore, this enzyme increased basal secretion by 50%, and analysis of the incubation medium by HPLC demonstrated that the cells secreted biologically effective concentrations of adenosine. These results indicate that adenosine produced in culture tonically inhibits hormone release. In other target cells, adenosine inhibition is mediated by two types of binding sites: an extracellular Ri-site requiring an intact ribose moiety or an intracellular P-site requiring an intact purine ring. Four lines of evidence indicate that in GH4C1 cells, adenosine acts at an Ri-site. PIA, an Ri-site-specific agonist, was a potent inhibitor of hormone release (ED50 = 30 nM). Theophylline, an Ri-site antagonist, competitively inhibited the action of PIA (Ki = 2.4 microM). 3) 2'5'-Dideoxyadenosine, a P-site-specific agonist, did not inhibit PRL release even at a concentration of 1 mM. 4) Dipyridamole, an adenosine uptake inhibitor, did not reduce adenosine inhibition. In addition to its effect on basal secretion, PIA inhibited stimulation of hormone release by vasoactive intestinal peptide and TRH. PIA also reduced vasoactive intestinal peptide-stimulated cAMP accumulation by 75%, consistent with its action to inhibit adenylate cyclase via Ri receptors in other targets. Since PIA inhibition of PRL release and cAMP accumulation was not additive with the effects of SRIF and carbamyl choline, these inhibitors may act via a common rate- limiting step. Our results demonstrate that adenosine activates an Ri- type of adenosine receptor in GH4C1 cells and that the production of adenosine under normal culture conditions causes autocrine inhibition of secretion.
This article has been cited by other articles:
![]() |
B. M. Lewis, A. Pexa, K. Francis, V. Verma, A. M. McNicol, M. Scanlon, A. Deussen, W. H. Evans, D. A. Rees, and J. Ham Adenosine stimulates connexin 43 expression and gap junctional communication in pituitary folliculostellate cells FASEB J, December 1, 2006; 20(14): 2585 - 2587. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Rees, M. D. Lewis, B. M. Lewis, P. J. Smith, M. F. Scanlon, and J. Ham Adenosine-Regulated Cell Proliferation in Pituitary Folliculostellate and Endocrine Cells: Differential Roles for the A1 and A2B Adenosine Receptors Endocrinology, June 1, 2002; 143(6): 2427 - 2436. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Hipkin, J. Friedman, R. B. Clark, C. M. Eppler, and A. Schonbrunn Agonist-induced Desensitization, Internalization, and Phosphorylation of the sst2A Somatostatin Receptor J. Biol. Chem., May 23, 1997; 272(21): 13869 - 13876. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |